Posted by Michael Wonder on 07 May 2020
CSL Behring Australia commences development of treatment for serious cases of COVID-19
6 May 2020 - Plasma-derived therapeutic with potential to treat serious complications of COVID-19.
CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will begin immediate onshore development of an anti-SARS-CoV-2 plasma product with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation.
The investigational product, to be known as COVID-19 Immunoglobulin, will be developed by CSL Behring Australia at its advanced manufacturing facility located in Broadmeadows, Victoria.
